

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/084,453	02/28/2002	Linqiu Cao	219425US0	4985	
22850	50 7590 11/30/2005		EXAMINER		
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C. 1940 DUKE STREET			TRAN, THAO T		
	IA, VA 22314		ART UNIT	PAPER NUMBER	
			1711		
				DATE MAILED: 11/30/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)		
	10/084,453	CAO ET AL.		
Office Action Summary	Examiner	Art Unit		
	Thao T. Tran	1711		
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address		
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	l. ely filed the mailing date of this communication. 0 (35 U.S.C. § 133)		
Status				
Responsive to communication(s) filed on 31 Au This action is FINAL. 2b) ☐ This Since this application is in condition for allowant closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro			
Disposition of Claims				
4) ☐ Claim(s) 1 and 22-45 is/are pending in the apple 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1 and 22-45 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	vn from consideration.			
Application Papers				
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the conference of the	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is objected to be a second to be a secon	37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119				
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ■ All b) ■ Some * c) ■ None of: 1. ■ Certified copies of the priority documents have been received. 2. ■ Certified copies of the priority documents have been received in Application No 3. ■ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary (Paper No(s)/Mail Dai 5) Notice of Informal Pa 6) Other:	te		

Application/Control Number: 10/084,453

Art Unit: 1711

Page 2

DETAILED ACTION

Response to Amendment

- 1. This is in response to the Amendment filed on 8/31/2005.
- 2. Claims 1 and 22-44 are currently pending in this application. In this amendment, claim 39 has been amended.
- 3. In view of the Office action of 6/01/2005, the rejection of claims 39-44 as being anticipated by Margolin et al. (US Pat. 6,359,118), has been withdrawn due to the Amendment made thereto.
- 4. Upon further consideration, the allowance of claims 1 and 22-38 has been withdrawn.
- 5. A new rejection is issued as follows.

Claim Rejections - 35 USC § 103

- 6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 7. Claims 1 and 22-44 are rejected under 35 U.S.C. 103(a) as being unpatentable over Margolin et al. (US Pat. 6,359,118).

Margolin teaches crosslinked enzyme (glycoprotein) aggregates (crystals) and a method of preparing (see abstract); the method comprising providing a plurality of enzyme molecules

Art Unit: 1711

(glucose oxidase), aggregating the enzyme molecules by a precipitating agent (polyethylene glycol) (see col. 17, ln. 51-52, Example 2); crosslinking the aggregated enzyme molecules to one another with a crosslinking agent (see col. 9, ln. 1-10).

Margolin further teaches the enzymes to be lipase, esterase, or protease (see col. 8, ln. 28-34). The crosslinking agent is a combination of glutaraldehyde and a diaminoalkane (diaminooctane) (see col. 25, ln. 67, bridging col. 26, ln. 3), that can be used to crosslink a protein molecule to another protein molecule (see col. 5, ln. 35-37).

Margolin further teaches the enzyme crystals being combined with solid carrier materials (see col. 11, ln. 5-6, 25-26; col. 12, ln. 16-17). Although Margolin is silent with respect to the enzyme crystals being crosslinked with the carrier and that the aldehyde groups in the crosslinker spaced further apart than the aldehyde groups in glutaraldehyde, since the reference teaches the same enzyme crystals with the same crosslinking agent to the presently claimed invention, the reference's enzyme crystals would inherently be crosslinked to the carrier and the spacing of the aldehyde groups in the crosslinker and in glutaraldehyde would inherently be the same as that in the presently claimed invention.

Margolin differs from the presently claimed invention in that the reference does not teach the crosslinking agent is prepared by combining a second compound and a first compound in a specific molar ratio.

However, it would have been obvious to one of ordinary skill in the art, at the time the invention was made, that the ratio of the two compounds would have been determined by routine experimentation in order to obtain the properties desired of the product.

Application/Control Number: 10/084,453

Art Unit: 1711

Page 4

Response to Arguments

8. Applicant's arguments with respect to the rejection of claims 39-44 have been considered but are most in view of the new ground(s) of rejection.

Contact Information

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Thao T. Tran whose telephone number is 571-272-1080. The examiner can normally be reached on Monday-Friday, from 9:00 a.m. - 5:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Seidleck can be reached on 571-272-1078. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

tt

November 28, 2005

THAOT.TRAN
PATENT EXAMINER